| Followers | 65 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Sunday, September 08, 2019 8:41:40 AM
That is only if the FDA agrees to ignore a partial failure, and if they are as hostile to NWBO and in the pocket of hostile Big Pharma companies as management apologists claim, then FDA could well say “Run another trial before we will approve.”
The only possible way to combat that bias if it exists would be to get the public and opinion makers fired up about DCVax L before a decision on that is rendered but we’ve all seen that again NWBO has lost the ability to get their message out there, an ability that drew once-trusting people like myself.
My hope is that the hire from Merck shows that the apologists are wrong about the attitude of FDA and Big Pharma and that Linda Powers has gotten past the whole “They only bring a checkbook to the table mentality” and is willing to work with them to bet a good deal.
The only possible way to combat that bias if it exists would be to get the public and opinion makers fired up about DCVax L before a decision on that is rendered but we’ve all seen that again NWBO has lost the ability to get their message out there, an ability that drew once-trusting people like myself.
My hope is that the hire from Merck shows that the apologists are wrong about the attitude of FDA and Big Pharma and that Linda Powers has gotten past the whole “They only bring a checkbook to the table mentality” and is willing to work with them to bet a good deal.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
